CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)
DOI 10.1055/s-0034-1388557
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Hilpert, C Kurzeder, B Schmalfeldt, P Neuser, N de Gregorio, J Pfisterer, TW Park-Simon, S Mahner, W Schröder, HJ Lück, M Heubner, L Hanker, F Thiel, G Emons
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Inhibition of mTOR with temsirolimus (T) might be an efficacious treatment of patients with epithelial ovarian cancer (OC) or endometrial cancer (EC). Methods: Patients (pts) with platinum and taxane resistant OC (n = 22) or with advanced/recurrent EC, who had not received previous chemotherapy (n = 22) were treated with weekly IV infusions of T (25 mg). Primary endpoint was progression free survival aft…
Zitieren
Zitierempfehlung
F Hilpert, C Kurzeder, B Schmalfeldt, P Neuser, N de Gregorio, J Pfisterer, TW Park-Simon, S Mahner, W Schröder, HJ Lück, M Heubner, L Hanker, F Thiel, G Emons (2014) Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8). Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-0034-1388557
Mit CareLit weiterarbeiten